Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iterum TherapeuticsITRMF Buyback Yield % is -3,078,600.00 as of Aug. 11, 2026. The stock has 4 warning signs investors should review. Among 725 Biotechnology companies, Iterum Therapeutics ranks worse than 100% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Iterum Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Iterum Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ITRMF vs HEPA, MTNB, VIVS: Buyback Yield % Comparison
For the Biotechnology subindustry, Iterum Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iterum Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Iterum Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Buyback Yield % of -3,078,600.00 mean?
Iterum Therapeutics (ITRMF) has a Buyback Yield % of -3,078,600.00 as of Aug. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Iterum Therapeutics and its competitors. According to the industry distribution chart, Iterum Therapeutics ranks #725 out of 725 companies in the Biotechnology industry.
Is Iterum Therapeutics' Buyback Yield % too high?
Iterum Therapeutics' current Buyback Yield % is -3,078,600.00. Based on the distribution chart, Iterum Therapeutics ranks #725 out of 725 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Iterum Therapeutics' Buyback Yield % compare to HEPA and MTNB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #725 out of 725 companies for Buyback Yield %. This places Iterum Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current Buyback Yield % is -3,078,600.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Buyback Yield % of -3,078,600.00. The current Buyback Yield % is -3,078,600.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Buyback Yield % is -3,078,600.00 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITRMF has been successfully added to your 
